Celgene (CELG) Wins FDA Approval for Pomalyst in Multiple Myeloma
Tweet
Share
E-mailGet Alerts CELG Hot Sheet
Join SI Premium – FREE
Celgene Corp (NASDAQ: CELG) is said to have won FDA approval for pomalidomide in multiple myeloma.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Eli Lilly (LLY) sleep apnea study data seen as a win, stock gains
- Cybin Inc (CYBN) Reports Publication of Research Manuscript in the Journal of Medicinal Chemistry
- Evotec (EVO) And Variant Bio Enter Strategic Partnership To Discover And Develop Fibrosis Treatments
Create E-mail Alert Related Categories
FDA, Insiders' BlogSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
